ADVANCING INCLUSIVE RESEARCH: ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS

Owen Garrick; Ruben Mesa; Andrea Ferris; Edward S. Kim; Edith Mitchell; Otis W. Brawley; John Carpten; Keith D. Carter; Joseph Coney; Robert Winn; Stephanie Monroe; Fabian Sandoval; Edith Perez; Mitzi Williams; Evan Grove; Quita Highsmith; Nicole Richie; Susan M. Begelman; Asha S. Collins; Jamie Freedman; Melissa S. Gonzales; Gerren Wilson

doi:10.18865/ed.32.1.61

ADVANCING INCLUSIVE RESEARCH: ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS

Owen Garrick, Ruben Mesa, Andrea Ferris, Edward S. Kim, Edith Mitchell, Otis W. Brawley, John Carpten, Keith D. Carter, Joseph Coney, Robert Winn, Stephanie Monroe, Fabian Sandoval, Edith Perez, Mitzi Williams, Evan Grove, Quita Highsmith, Nicole Richie, Susan M. Begelman, Asha S. Collins, Jamie FreedmanMelissa S. Gonzales, Gerren Wilson

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person committee dedicated to developing strategies to increase clinical research participation. To help improve the recruitment and retention of patients of color, this article chronicles our efforts to tangibly address the clinical research barriers at the system, study, and patient levels over the last four years. These efforts are one of the initial steps to fully realize the promise of personalized health care and provide increased patient benefit at less cost to society. Instead of simply acknowledging the problem, here we illuminate the collaborative and multilevel strategies that have been effective in delivering meaningful progress for patients.

Original language	English (US)
Pages (from-to)	61-68
Number of pages	8
Journal	Ethnicity and Disease
Volume	32
Issue number	1
DOIs	https://doi.org/10.18865/ed.32.1.61
State	Published - 2022

Keywords

COVID-19
Clinical trial design
Health care disparities
Minority health
Personalized health care

ASJC Scopus subject areas

Epidemiology

Access to Document

10.18865/ed.32.1.61

Cite this

Garrick, O., Mesa, R., Ferris, A., Kim, E. S., Mitchell, E., Brawley, O. W., Carpten, J., Carter, K. D., Coney, J., Winn, R., Monroe, S., Sandoval, F., Perez, E., Williams, M., Grove, E., Highsmith, Q., Richie, N., Begelman, S. M., Collins, A. S., ... Wilson, G. (2022). ADVANCING INCLUSIVE RESEARCH: ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS. Ethnicity and Disease, 32(1), 61-68. https://doi.org/10.18865/ed.32.1.61

Garrick, O, Mesa, R, Ferris, A, Kim, ES, Mitchell, E, Brawley, OW, Carpten, J, Carter, KD, Coney, J, Winn, R, Monroe, S, Sandoval, F, Perez, E, Williams, M, Grove, E, Highsmith, Q, Richie, N, Begelman, SM, Collins, AS, Freedman, J, Gonzales, MS & Wilson, G 2022, 'ADVANCING INCLUSIVE RESEARCH: ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS', Ethnicity and Disease, vol. 32, no. 1, pp. 61-68. https://doi.org/10.18865/ed.32.1.61

@article{199bd225d0c34ff680839ac03abc7c13,

title = "ADVANCING INCLUSIVE RESEARCH: ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS",

abstract = "Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person committee dedicated to developing strategies to increase clinical research participation. To help improve the recruitment and retention of patients of color, this article chronicles our efforts to tangibly address the clinical research barriers at the system, study, and patient levels over the last four years. These efforts are one of the initial steps to fully realize the promise of personalized health care and provide increased patient benefit at less cost to society. Instead of simply acknowledging the problem, here we illuminate the collaborative and multilevel strategies that have been effective in delivering meaningful progress for patients.",

keywords = "COVID-19, Clinical trial design, Health care disparities, Minority health, Personalized health care",

author = "Owen Garrick and Ruben Mesa and Andrea Ferris and Kim, {Edward S.} and Edith Mitchell and Brawley, {Otis W.} and John Carpten and Carter, {Keith D.} and Joseph Coney and Robert Winn and Stephanie Monroe and Fabian Sandoval and Edith Perez and Mitzi Williams and Evan Grove and Quita Highsmith and Nicole Richie and Begelman, {Susan M.} and Collins, {Asha S.} and Jamie Freedman and Gonzales, {Melissa S.} and Gerren Wilson",

note = "Funding Information: Ruben Mesa - Receives consultant fees from Genentech/Novartis/Sierra Onc/LaJolla/ Pharma/Constellation; receives research support from Celgene/Incyte/Abbvie/Samus/ Genotech/Promedior/CTI/ Constellation Funding Information: Susan Begelman - Employee of Genentech, a member of Roche Group, and owner of Roche stock. Member, The Genentech Foundation Board, a U.S.-based, private charitable foundation whose donations are made possible by contributions from Genentech Otis Brawley - Receives consulting fees from: Genentech, EGRX, Grail; Meeting support from Lyell Immunopharma, PDS Biopharma, Jackson Labs; and owns stock or stock options in Lyell Immunopharma, PDS Biopharma, Grail. Publisher Copyright: {\textcopyright} 2022 Ethnicity and Disease, Inc.. All rights reserved.",

year = "2022",

doi = "10.18865/ed.32.1.61",

language = "English (US)",

volume = "32",

pages = "61--68",

journal = "Ethnicity and Disease",

issn = "1049-510X",

publisher = "ISHIB",

number = "1",

}

TY - JOUR

T1 - ADVANCING INCLUSIVE RESEARCH

T2 - ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS

AU - Garrick, Owen

AU - Mesa, Ruben

AU - Ferris, Andrea

AU - Kim, Edward S.

AU - Mitchell, Edith

AU - Brawley, Otis W.

AU - Carpten, John

AU - Carter, Keith D.

AU - Coney, Joseph

AU - Winn, Robert

AU - Monroe, Stephanie

AU - Sandoval, Fabian

AU - Perez, Edith

AU - Williams, Mitzi

AU - Grove, Evan

AU - Highsmith, Quita

AU - Richie, Nicole

AU - Begelman, Susan M.

AU - Collins, Asha S.

AU - Freedman, Jamie

AU - Gonzales, Melissa S.

AU - Wilson, Gerren

N1 - Funding Information: Ruben Mesa - Receives consultant fees from Genentech/Novartis/Sierra Onc/LaJolla/ Pharma/Constellation; receives research support from Celgene/Incyte/Abbvie/Samus/ Genotech/Promedior/CTI/ Constellation Funding Information: Susan Begelman - Employee of Genentech, a member of Roche Group, and owner of Roche stock. Member, The Genentech Foundation Board, a U.S.-based, private charitable foundation whose donations are made possible by contributions from Genentech Otis Brawley - Receives consulting fees from: Genentech, EGRX, Grail; Meeting support from Lyell Immunopharma, PDS Biopharma, Jackson Labs; and owns stock or stock options in Lyell Immunopharma, PDS Biopharma, Grail. Publisher Copyright: © 2022 Ethnicity and Disease, Inc.. All rights reserved.

PY - 2022

Y1 - 2022

N2 - Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person committee dedicated to developing strategies to increase clinical research participation. To help improve the recruitment and retention of patients of color, this article chronicles our efforts to tangibly address the clinical research barriers at the system, study, and patient levels over the last four years. These efforts are one of the initial steps to fully realize the promise of personalized health care and provide increased patient benefit at less cost to society. Instead of simply acknowledging the problem, here we illuminate the collaborative and multilevel strategies that have been effective in delivering meaningful progress for patients.

AB - Well-characterized disparities in clinical research have disproportionately affected patients of color, particularly in underserved communities. To tackle these barriers, Genentech formed the External Council for Advancing Inclusive Research, a 14-person committee dedicated to developing strategies to increase clinical research participation. To help improve the recruitment and retention of patients of color, this article chronicles our efforts to tangibly address the clinical research barriers at the system, study, and patient levels over the last four years. These efforts are one of the initial steps to fully realize the promise of personalized health care and provide increased patient benefit at less cost to society. Instead of simply acknowledging the problem, here we illuminate the collaborative and multilevel strategies that have been effective in delivering meaningful progress for patients.

KW - COVID-19

KW - Clinical trial design

KW - Health care disparities

KW - Minority health

KW - Personalized health care

UR - http://www.scopus.com/inward/record.url?scp=85123972525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123972525&partnerID=8YFLogxK

U2 - 10.18865/ed.32.1.61

DO - 10.18865/ed.32.1.61

M3 - Article

C2 - 35106045

AN - SCOPUS:85123972525

SN - 1049-510X

VL - 32

SP - 61

EP - 68

JO - Ethnicity and Disease

JF - Ethnicity and Disease

IS - 1

ER -

ADVANCING INCLUSIVE RESEARCH: ESTABLISHING COLLABORATIVE STRATEGIES TO IMPROVE DIVERSITY IN CLINICAL TRIALS

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this